Substituted 3-cyanoquinolines as MEK inhibitors

Abstract

The invention concerns quinoline derivatives of Formula (I) wherein each of Z 1 , m, R 1 , n, R 3 , Z 2 and R 14 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive or anti-proliferative agent in the containment and/or treatment of solid tumour disease.

1 . (canceled)  
   
   
       2 . The method of  claim 16  or  claim 17  which comprises the administration of a quinoline derivative of the Formula I, or a pharmaceutically acceptable salt thereof, wherein R 1 , R 3 , Z 1 , Z 2 , m and n have any of the meanings defined in  claim 16  or  claim 17  and 
 R 14  is selected from cyano, formyl, carboxy, carbamoyl, methoxycarbonyl, vinyl, ethoxycarbonyl,  N -methylcarbamoyl,  N -ethylcarbamoyl,  N,N -dimethylcarbamoyl,  N -ethyl- N -methylcarbamoyl,  N,N -diethylcarbamoyl, acetyl, propionyl, chloromethyl, 2-chloroethyl, 3-chloropropyl, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, methoxymethyl, 2-methoxyethyl, 3-methoxypropyl or from a group of the formula:      —X 7 -Q 5      wherein X 7  is a direct bond or CO and Q 5  is pyridin-2-yl, 1-pyrrolidinyl, morpholino, 1,1-dioxotetrahydro-4 H -1,4-thiazin-4-yl, piperidino, 1-homopiperidinyl, piperazin-1-yl, homopiperazin-1-yl, 1-pyrrolidinylmethyl, morpholinomethyl, piperidinomethyl, 1-homopiperidinylmethyl, 1,1-dioxotetrahydro-4 H -1,4-thiazin-4-ylmethyl, piperazin-1-ylmethyl, homopiperazin-1-ylmethyl or 3-morpholinopropyl,    and wherein any CH 2  or CH 3  group within a R 14  substituent optionally bears on each said CH 2  or CH 3  group one or more fluoro, chloro or methyl groups or a substituent selected from hydroxy, amino, methoxy, methylamino, dimethylamino, acetoxy, acetamido and  N -methylacetamido,    and wherein any heteroaryl or heterocyclyl group within a substituent on R 14  optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from hydroxy, amino, carbamoyl, methyl, ethyl, allyl, 2-propynyl, methoxy, methylsulphonyl,  N -methylcarbamoyl,  N,N -dimethylcarbamoyl and acetyl, or optionally bears 1 substituent selected from a group of the formula:      —X 9 —R 17      wherein X 9  is a direct bond and R 17  is 2-fluoroethyl, 2-hydroxyethyl, 3-hydroxypropyl, 2-methoxyethyl, 3-methoxypropyl, cyanomethyl, aminomethyl, methylaminomethyl, dimethylaminomethyl, acetamidomethyl, methoxycarbonylaminomethyl, ethoxycarbonylaminomethyl or tert-butoxycarbonylaminomethyl,    and wherein any heterocyclyl group within a substituent on R 14  optionally bears 1 or 2 oxo substituents.    
   
   
       3 . The method of  claim 16  or  claim 17  which comprises the administration of a quinoline derivative of the Formula I wherein: 
 Z 1  is O or NH;    m is 1 and the R 1  group is located at the 5-, 6- or 7-position or m is 2 and each R 1  group, which may be the same or different, is located at the 5- and 7-positions or at the 6- and 7-positions and R 1  is selected from hydroxy, amino, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, isopropoxy, butoxy, pent-4-ynyloxy, hex-5-ynyloxy, methylamino, ethylamino, dimethylamino, diethylamino, acetamido, propionamido, 2-imidazol-1-ylethoxy, 2-(1,2,4-triazol-1-yl)ethoxy, tetrahydrofuran-3-yloxy, tetrahydropyran-4-yloxy, 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, 4-pyrrolidin-1-ylbutoxy, pyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy, 2-pyrrolidin-2-ylethoxy, 3-pyrrolidin-2-ylpropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 4-morpholinobutoxy, 2-(1,1-dioxotetrahydro-4 H -1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-4 H -1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, 4-piperidinobutoxy, piperidin-3-yloxy, piperidin-4-yloxy, piperidin-3-ylmethoxy, piperidin-4-ylmethoxy, 2-piperidin-3-ylethoxy, 3-piperidin-3-ylpropoxy, 2-piperidin-4-ylethoxy, 3-piperidin-4-ylpropoxy, 2-homopiperidin-1-ylethoxy, 3-homopiperidin-1-ylpropoxy, 2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy, 4-piperazin-1-ylbutoxy, 2-homopiperazin-1-ylethoxy and 3-homopiperazin-1-ylpropoxy,    and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R 1  substituent are optionally separated by the insertion into the chain of a group selected from O, NH, N(Me), CH═CH and C≡C,    and wherein any CH 2  or CH 3  group within a R 1  substituent optionally bears on each said CH 2  or CH 3  group one or more fluoro or chloro groups or a substituent selected from hydroxy, amino, methoxy, methylsulphonyl, methylamino, dimethylamino, diethylamino,  N -ethyl- N -methylamino,  N -isopropyl- N -methylamino,  N -methyl- N -propylamino and acetoxy,    and wherein any heteroaryl or heterocyclyl group within a substituent on R 1  optionally bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chloro, trifluoromethyl, hydroxy, amino, carbamoyl, methyl, ethyl, methoxy,  N -methylcarbamoyl and  N,N -dimethylcarbamoyl and a pyrrolidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl or homopiperazin-1-yl group within a R 1  substituent is optionally  N -substituted with allyl, methylsulphonyl, acetyl, 2-fluoroethyl, 3-fluoropropyl, 2-methoxyethyl, 3-methoxypropyl, cyanomethyl, 2-aminoethyl, 3-aminopropyl, 2-methylaminoethyl, 3-methylaminopropyl, 2-dimethylaminoethyl, 3-dimethylaminopropyl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl, 2-morpholinoethyl, 3-morpholinopropyl, 2-piperidinoethyl, 3-piperidinopropyl, 2-piperazin-1-ylethyl or 3-piperazin-1-ylpropyl, the last 8 of which substituents each optionally bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chloro, methyl and methoxy,    and wherein any heterocyclyl group within a substituent on R 1  optionally bears 1 or 2 oxo substituents;    n is 0 or 1 and the R 3  group, if present, is located at the 5- or 6-position of the 1,3-benzodioxol-4-yl group and is selected from fluoro, chloro, bromo, trifluoromethyl, cyano, hydroxy, methyl, ethyl, vinyl, allyl, ethynyl, methoxy and ethoxy;    Z 2  is a C≡C or CH═CH group; and    R 14  is selected from cyano, formyl, carboxy, carbamoyl, methoxycarbonyl, vinyl, ethoxycarbonyl,  N -methylcarbamoyl,  N -ethylcarbamoyl,  N,N -dimethylcarbamoyl,  N -ethyl- N -methylcarbamoyl,  N,N -diethylcarbamoyl, acetyl, propionyl, chloromethyl, 2-chloroethyl, 3-chloropropyl, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, methoxymethyl, 2-methoxyethyl, 3-methoxypropyl, cyanomethyl, 2-cyanoethyl, 3-cyanopropyl, methylaminomethyl, ethylaminomethyl, 2-methylaminoethyl, 3-methylaminopropyl, 2-ethylaminoethyl, 3-ethylaminopropyl, dimethylaminomethyl, 2-dimethylaminoethyl, 3-dimethylaminopropyl, acetamidomethyl, 2-acetamidoethyl and 3-acetamidopropyl, or from a group of the formula:      —X 7 -Q 5      wherein X 7  is a direct bond or CO and Q 5  is pyridin-2-yl, 1-pyrrolidinyl, morpholino, 1,1-dioxotetrahydro-4 H -1,4-thiazin-4-yl, piperidino, 1-homopiperidinyl, piperazin-1-yl, homopiperazin-1-yl, 1-pyrrolidinylmethyl, morpholinomethyl, piperidinomethyl, 1-homopiperidinylmethyl, 1,1-dioxotetrahydro-4 H -1,4-thiazin-4-ylmethyl, piperazin-1-ylmethyl, homopiperazin-1-ylmethyl or 3-morpholinopropyl,    and wherein any CH 2  or CH 3  group within a R 14  substituent optionally bears on each said CH 2  or CH 3  group one or more fluoro, chloro or methyl groups or a substituent selected from hydroxy, amino, methoxy, methylamino, dimethylamino, acetoxy, acetamido and  N -methylacetamido,    and wherein any heteroaryl or heterocyclyl group within a substituent on R 14  optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from hydroxy, amino, carbamoyl, methyl, ethyl, allyl, 2-propynyl, methoxy, methylsulphonyl,  N -methylcarbamoyl,  N,N -dimethylcarbamoyl and acetyl, or optionally bears 1 substituent selected from a group of the formula:      —X 9 —R 7      wherein X 9  is a direct bond and R 17  is 2-hydroxyethyl, 3-hydroxypropyl, 2-methoxyethyl, 3-methoxypropyl, cyanomethyl, aminomethyl, methylaminomethyl, dimethylaminomethyl, acetamidomethyl, methoxycarbonylaminomethyl, ethoxycarbonylaminomethyl or tert-butoxycarbonylaminomethyl,    and wherein any heterocyclyl group within a substituent on R 14  optionally bears 1 or 2 oxo substituents;    or a pharmaceutically-acceptable acid-addition salt thereof.    
   
   
       4 . The method of  claim 16  or  claim 17  which comprises the administration of a quinoline derivative of the Formula I, or a pharmaceutically acceptable salt thereof, wherein R 1 , R 3 , R 14 , Z 2 , m and n have any of the meanings defined in  claim 1  and Z 1  is NH.  
   
   
       5 . The method of  claim 16  or  claim 17  which comprises the administration of a quinoline derivative of the Formula I, or a pharmaceutically acceptable salt thereof, wherein R 1 , R 3 , R 14 , Z 1 , m and n have any of the meanings defined in  claim 1  and Z 2  is a C≡C group.  
   
   
       6 . The method of  claim 16  or  claim 17  which comprises the administration of a quinoline derivative of the Formula I, or a pharmaceutically acceptable salt thereof, wherein R 1 , R 3 , R 14 , Z 1 , Z 2 , m and n have any of the meanings defined in  claim 1  and the Z 2 -R 14  group is located at the 7-position on the 1,3-benzodioxol-4-yl group.  
   
   
       7 . The method of  claim 16  or  claim 17  which comprises the administration of a quinoline derivative of the Formula I wherein: 
 Z 1  is NH;    m is 2 and the first R 1  group is a 6-methoxy group and the second R 1  group is located at the 7-position and is selected from methoxy, ethoxy, 2-fluoroethoxy, 2-chloroethoxy, 3-fluoropropoxy, 3-chloropropoxy, 2-(2-chloroethoxy)ethoxy, 2-(2-methoxyethoxy)ethoxy, 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 2-(1,1-dioxotetrahydro-4 H -1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-4 H -1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy, 3-(4-allylpiperazin-1-yl)propoxy, 3-(4-methylsulphonylpiperazin-1-yl)propoxy, 3-(4-acetylpiperazin-1-yl)propoxy, 2-(4-cyanomethylpiperazin-1-yl)ethoxy, 3-(4-cyanomethylpiperazin-1-yl)propoxy, 2-[4-(2-fluoroethyl)piperazin-1-yl]ethoxy, 3-[4-(2-fluoroethyl)piperazin-1-yl]propoxy, 2-(3-oxopiperazin-1-yl)ethoxy, 3-(3-oxopiperazin-1-yl)propoxy, 2-(2-pyrrolidin-1-ylethoxy)ethoxy and 2-fluoro-3-(4-hydroxypiperidin-1-yl)propoxy;    n is 0 or n is 1 and R 3  is a fluoro or chloro group located at the 5-position of the 1,3-benzodioxol-4-yl group;    the -Z 2 -R 14  group is located at the 7-position on the 1,3-benzodioxol-4-yl group,    Z 2  is a C≡C group; and    R 14  is selected from vinyl, hydroxymethyl, methoxymethyl, dimethylaminomethyl, pyridin-2-yl, 1-pyrrolidinylmethyl, morpholinomethyl, piperidinomethyl, 1,1-dioxotetrahydro-4 H -1,4-thiazin-4-ylmethyl and piperazin-1-ylmethyl;    or a pharmaceutically-acceptable acid-addition salt thereof.    
   
   
       8 . The method of  claim 16  or  claim 17  which comprises the administration of a quinoline derivative of the Formula I wherein 
 Z 1  is NH;    m is 2 and the first R 1  group is located at the 5-position and is selected from  N -methylpiperidin-4-yloxy and tetrahydro-2H-pyran-4-yloxy and the second R 1  group is located at the 7-position and is selected from methoxy and 3-morpholinopropoxy,    n is 0 or n is 1 and R 3  is located at the 5-position of the 1,3-benzodioxol-4-yl group and is a chloro group;    the -Z 2 -R 14  group is located at the 7-position on the 1,3-benzodioxol-4-yl group,    Z 2  is a C≡C group; and    R 14  is selected from methoxymethyl and 2-methoxyethyl;    or a pharmaceutically-acceptable acid-addition salt thereof.    
   
   
       9 . The method of  claim 16  or  claim 17  which comprises the administration of a quinoline derivative of the Formula I and selected from 
 7-[3-(4-acetylpiperazin-1-yl)propoxy]-3-cyano-6-methoxy-4-[4-(3-methoxyprop-1-ynl)-2,3-methylenedioxyanilino]quinoline;    3-cyano-6,7-dimethoxy-4-[4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyanilino]quinoline;    3-cyano-6,7-dimethoxy-4-[6-chloro-4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxy anilino]quinoline;    3-cyano-7-ethoxy-6-methoxy-4-[4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyanilino]quinoline;    3-cyano-7-{3-[4-(2-fluoroethyl)piperazin-1-yl]propoxy}-6-methoxy-4-[4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyanilino]quinoline;    3-cyano-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]-4-[4-(3-methoxyprop-1ynyl)-2,3-methylenedioxyanilino]quinoline;    3-cyano-6-methoxy-4-[4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyanilino]-7-[3-morpholinopropoxy]quinoline;    4-[6-chloro-4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyanilino]-3-cyano-6-methoxy-7-[3-morpholinopropoxy]quinoline;    3-cyano-7-[3-(1,1-dioxotetrahydro-4 H -thiazin-4-yl)propoxy]-6-methoxy-4-[4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyanilino]quinoline;    3-cyano-7-(2-fluoroethoxy)-6-methoxy-4-[4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyanilino]quinoline;    3-cyano-6-methoxy-4-[4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyanilino]-7-[3-(3-oxopiperazin-1-yl)propoxy]quinoline;    3-cyano-6-methoxy-4-[6-chloro-4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyanilino]-7-[3-(3-oxopiperazin-1-yl)propoxy]quinoline;    3-cyano-6-methoxy-4-[4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyanilino]-7-[2-(2-pyrrolidin-1-ylethoxy)ethoxy]quinoline;    3-cyano-6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]-4-[4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyanilino]quinoline;    3-cyano-4-[6-chloro-4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyanilino]-7-methoxy-5-[(1-methylpiperidin-4-yl)oxy]quinoline;    3-cyano-7-methoxy-5-[(1-methylpiperidin-4-yl)oxy]-4-[4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyanilino]quinoline;    3-cyano-7-(3-morpholin-4-ylpropoxy)-5-(tetrahydro-2H-pyran-4-yloxy)-4-[4-(3-methoxyprop-1-ynyl)-2,3 -methylenedioxyanilino]quinoline;    3-cyano-7-methoxy-4-[4-(4-methoxybut-1-ynyl)-2,3-methylenedioxyanilino]-5-[(1-methylpiperidin-4-yl)oxy]quinoline;    4-[(4-but-3-en-1-ynyl-2,3-methylendioxy)anilino]-3-cyano-7-methoxy-5-[(1-methylpiperidin-4-yl)oxy]quinoline;    3-cyano-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]-4-[6-fluoro-4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyanilino]quinoline;    3-cyano-6-methoxy-7-[2-fluoro-3-(4-hydroxypiperidin-1-yl)propoxy]-4-[4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyanilino]quinoline;    3-cyano-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]-4-[4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyanilino]quinoline; and    3-cyano-6,7-dimethoxy-4-[4-(pyridin-2-ylethynyl)-2,3-methylenedioxyanilino]quinoline, 
 or a pharmaceutically acceptable acid addition salt thereof.  
   
   
   
       10 - 15 . (canceled)  
   
   
       16 . A method for inhibiting a MEK enzyme in a warm-blooded animal in need thereof which comprises administering to said animal an effective amount of a quinoline derivative of the Formula I  
     
       
         
         
             
             
         
       
     
     wherein Z 1  is an O, S, SO, SO 2 , N(R 2 ) or C(R 2 ) 2  group, wherein each R 2  group, which may be the same or different, is hydrogen or (1-6C)alkyl; 
 m is 0, 1, 2, 3 or 4;  
 each R 1  group, which may be the same or different, is selected from halogeno, trifluoromethyl, cyano, isocyano, nitro, hydroxy, mercapto, amino, formyl, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl,  N -(1-6C)alkylcarbamoyl,  N,N -di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino,  N- -(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino,  N -(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino,  N -(1-6C)alkyl-(3-6C)alkynoylamino,  N -(1-6C)alkylsulphamoyl,  N,N -di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino,  N -(1-6C)alkyl-(1-6C)alkanesulphonylamino or from a group of the formula:  
   Q 1 -X 1 — 
 wherein X 1  is a direct bond or is selected from O, S, SO, SO 2 , N(R 4 ), CO, CH(OR 4 ), CON(R 4 ), N(R 4 )CO, SO 2 N(R 4 ), N(R 4 )SO 2 , OC(R 4 ) 2 , SC(R 4 ) 2  and N(R 4 )C(R 4 ) 2 , wherein R 4  is hydrogen or (1-6C)alkyl, and Q 1  is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, or (R 1 ) m  is (1-3C)alkylenedioxy,  
 and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R 1  substituent are optionally separated by the insertion into the chain of a group selected from O, S, SO, SO 2 , N(R 5 ), CO, CH(OR 5 ), CON(R 5 ), N(R 5 )CO, SO 2 N(R 5 ), N(R 5 )SO 2 , CH═CH and C≡C wherein R 5  is hydrogen or (1-6C)alkyl or, when the inserted group is N(R 5 ), R 5  may also be (2-6C)alkanoyl,  
 and wherein any CH 2 ═CH— or HC≡C— group within a R 1  substituent optionally bears at the terminal CH 2 ═ or HC≡ position a substituent selected from halogeno, carboxy, carbamoyl, (1-6C)alkoxycarbonyl,  N -(1-6C)alkylcarbamoyl,  N,N -di-[(1-6C)alkyl]carbamoyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl or from a group of the formula:  
   Q 2 -X 2 — 
 wherein X 2  is a direct bond or is selected from CO and N(R 6 )CO, wherein R 6  is hydrogen or (1-6C)alkyl, and Q 2  is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,  
 and wherein any CH, CH 2  or CH 3  group within a R 1  substituent optionally bears on each said CH, CH 2  or CH 3  group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, amino, carboxy, carbamoyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl,  N -(1-6C)alkylcarbamoyl,  N,N -di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino,  N -(1-6C)alkyl-(2-6C)alkanoylamino,  N -(1-6C)alkylsulphamoyl,  N,N -di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino,  N -(1-6C)alkyl-(1-6C)alkanesulphonylamino or from a group of the formula:  
   —X 3 -Q 3    
 wherein X 3  is a direct bond or is selected from O, S, SO, SO 2 , N(R 7 ), CO, CH(OR 7 ), CON(R 7 ), N(R 7 )CO, SO 2 N(R 7 ), N(R 7 )SO 2 , C(R 7 ) 2 O, C(R 7 ) 2 S and N(R 7 )C(R 7 ) 2 , wherein R 7  is hydrogen or (1-6C)alkyl, and Q 3  is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,  
 and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on R 1  optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl,  N -(1-6C)alkylcarbamoyl,  N,N -di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino,  N -(1-6C)alkyl-(2-6C)alkanoylamino,  N -(1-6C)alkylsulphamoyl,  N,N -di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino,  N -(1-6C)alkyl-(1-6C)alkanesulphonylamino or from a group of the formula:  
   —X 4 —R 8    
 wherein X 4  is a direct bond or is selected from O and N(R 9 ), wherein R 9  is hydrogen or (1-6C)alkyl, and R 8  is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl or (1-6C)alkoxycarbonylamino-(1-6C)alkyl or from a group of the formula:  
   —X 5 -Q 4    
 wherein X 5  is a direct bond or is selected from O, N(R 10 ) and CO, wherein R 10  is hydrogen or (1-6C)alkyl, and Q 4  is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl which optionally bears 1 or 2 substituents, which may be the same or different, selected from halogeno, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl and (1-6C)alkoxy,  
 and wherein any heterocyclyl group within a substituent on R 1  optionally bears 1 or 2 oxo or thioxo substituents;  
 n is 0, 1, 2 or 3;  
 each R 3  group is halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl,  N -(1-6C)alkylcarbamoyl,  N,N -di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino,  N -(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino,  N -(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino,  N -(1-6C)alkyl-(3-6C)alkynoylamino,  N -(1-6C)alkylsulphamoyl,  N,N -di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino,  N -(1-6C)alkyl-(1-6C)alkanesulphonylamino or from a group of the formula:  
   —X 6 —R 11    
 wherein X 6  is a direct bond or is selected from O and N(R 12 ), wherein R 12  is hydrogen or (1-6C)alkyl, and R 11  is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl or di-[(1-6C)alkyl]amino-(1-6C)alkyl;  
 Z 2  is a C≡C or C(R 13 )═C(R 13 ) group, wherein each R 13  group, which may be the same or different, is hydrogen or (1-6C)alkyl; and  
 R 14  is selected from halogeno, cyano, isocyano, formyl, carboxy, carbamoyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxycarbonyl,  N -(1-6C)alkylcarbamoyl,  N,N -di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl,  N -(1-6C)alkylsulphamoyl,  N,N -di-[(1-6C)alkyl]sulphamoyl, halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl, (1-6C)alkoxycarbonylamino-(1-6C)alkyl or from a group of the formula:  
   —X 7 -Q 5    
 wherein X 7  is a direct bond or is selected from CO, CH(OR 15 ), CON(R 15 ) or SO 2 N(R 15 ), wherein R 15  is hydrogen or (1-6C)alkyl, and Q 5  is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,  
 and wherein any CH, CH 2  or CH 3  group within a R 14  substituent optionally bears on each said CH, CH 2  or CH 3  group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, amino, carboxy, carbamoyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl,  N -(1-6C)alkylcarbamoyl,  N,N -di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino,  N -(1-6C)alkyl-(2-6C)alkanoylamino,  N -(1-6C)alkylsulphamoyl,  N,N -di-[(1-6C)alkyl]-sulphamoyl, (1-6C)alkanesulphonylamino,  N -(1-6C)alkyl-(1-6C)alkanesulphonylamino or from a group of the formula:  
   —X 8 -Q 6    
 wherein X 8  is a direct bond or is selected from O, S, SO, SO 2 , N(R 16 ), CO, CH(OR 16 ), CON(R 16 ), N(R 16 )CO, SO 2 N(R 16 ), N(R 16 )SO 2 , C(R 16 ) 2 O, C(R 16 ) 2 S and N(R 16 ) 2 , wherein R 16  is hydrogen or (1-6C)alkyl, and Q 6  is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,  
 and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on R 14  optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl,  N -(1-6C)alkylcarbamoyl,  N,N -di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino,  N -(1-6C)alkyl-(2-6C)alkanoylamino,  N -(1-6C)alkylsulphamoyl,  N,N -di-[(1-6C)alkyl]-sulphamoyl, (1-6C)alkanesulphonylamino,  N -(1-6C)alkyl-(1-6C)alkanesulphonylamino or from a group of the formula:  
   —X 9 —R 17    
 wherein X 9  is a direct bond or is selected from O and N(R 18 ), wherein R 18  is hydrogen or (1-6C)alkyl, and R 17  is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl, (1-6C)alkoxycarbonylamino-(1-6C)alkyl, or from a group of the formula:  
   —X 10 -Q 7    
 wherein X 10  is a direct bond or is selected from O, N(R 19 ) and CO, wherein R 19  is hydrogen or (1-6C)alkyl, and Q 7  is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl which optionally bears 1 or 2 substituents, which may be the same or different, selected from halogeno, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl and (1-6C)alkoxy,  
 and wherein any heterocyclyl group within a substituent on R 14  optionally bears 1 or 2 oxo or thioxo substituents;  
 or a pharmaceutically-acceptable salt thereof.  
 
   
   
       17 . A method for the treatment and/or containment of a solid tumour disease in a warm-blooded animal in need thereof which comprises administering to said animal an effective amount of a quinoline derivative of the Formula I  
     
       
         
         
             
             
         
       
     
     wherein Z 1  is an O, S, SO, SO 2 , N(R 2 ) or C(R 2 ) 2  group, wherein each R 2  group, which may be the same or different, is hydrogen or (1-6C)alkyl; 
 m is 0, 1, 2, 3 or 4;  
 each R 1  group, which may be the same or different, is selected from halogeno, trifluoromethyl, cyano, isocyano, nitro, hydroxy, mercapto, amino, formyl, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl,  N -(1-6C)alkylcarbamoyl,  N,N -di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino,  N -(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino,  N -(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino,  N -(1-6C)alkyl-(3-6C)alkynoylamino,  N -(1-6C)alkylsulphamoyl,  N,N -di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino,  N -(1-6C)alkyl-(1-6C)alkanesulphonylamino or from a group of the formula:  
   Q 1 -X 1 — 
 wherein X 1  is a direct bond or is selected from O, S, SO, SO 2 , N(R 4 ), CO, CH(OR 4 ), CON(R 4 ), N(R 4 )CO, SO 2 N(R 4 ), N(R 4 )SO 2 , OC(R 4 ) 2 , SC(R 4 ) 2  and N(R 4 )C(R 4 ) 2 , wherein R 4  is hydrogen or (1-6C)alkyl, and Q 1  is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, or (R 1 ) m  is (1-3C)alkylenedioxy,  
 and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R 1  substituent are optionally separated by the insertion into the chain of a group selected from O, S, SO, SO 2 , N(R 5 ), CO, CH(OR 5 ), CON(R 5 ), N(R 5 )CO, SO 2 N(R 5 ), N(R 5 )SO 2 , CH═CH and C≡C wherein R 5  is hydrogen or (1-6C)alkyl or, when the inserted group is N(R 5 ), R 5  may also be (2-6C)alkanoyl,  
 and wherein any CH 2 ═CH— or HC≡C— group within a R 1  substituent optionally bears at the terminal CH 2 ═ or HC≡ position a substituent selected from halogeno, carboxy, carbamoyl, (1-6C)alkoxycarbonyl,  N -(1-6C)alkylcarbamoyl,  N,N -di-[(1 -6C)alkyl]carbamoyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl or from a group of the formula:  
   Q 2 -X 2 — 
 wherein X 2  is a direct bond or is selected from CO and N(R 6 )CO, wherein R 6  is hydrogen or (1-6C)alkyl, and Q 2  is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,  
 and wherein any CH, CH 2  or CH 3  group within a R 1  substituent optionally bears on each said CH, CH 2  or CH 3  group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, amino, carboxy, carbamoyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl,  N -(1-6C)alkylcarbamoyl,  N,N -di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino,  N -(1-6C)alkyl-(2-6C)alkanoylamino,  N -(1-6C)alkylsulphamoyl,  N,N -di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino,  N -(1-6C)alkyl-(1-6C)alkanesulphonylamino or from a group of the formula:  
   —X 3 -Q 3    
 wherein X 3  is a direct bond or is selected from O, S, SO, SO 2 , N(R 7 ), CO, CH(OR 7 ), CON(R 7 ), N(R 7 )CO, SO 2 N(R 7 ), N(R 7 )SO 2 , C(R 7 ) 2 O, C(R 7 ) 2 S and N(R 7 )C(R 7 ) 2 , wherein R 7  is hydrogen or (1-6C)alkyl, and Q 3  is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,  
 and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on R 1  optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl,  N -(1-6C)alkylcarbamoyl,  N,N -di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino,  N -(1-6C)alkyl-(2-6C)alkanoylamino,  N -(1-6C)alkylsulphamoyl,  N,N -di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino,  N -(1-6C)alkyl-(1-6C)alkanesulphonylamino or from a group of the formula:  
   —X 4 —R 8    
 wherein X 4  is a direct bond or is selected from O and N(R 9 ), wherein R 9  is hydrogen or (1-6C)alkyl, and R 8  is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl or (1-6C)alkoxycarbonylamino-(1-6C)alkyl or from a group of the formula:  
   —X 5 -Q 4    
 wherein X 5  is a direct bond or is selected from O, N(R 10 ) and CO, wherein R 10  is hydrogen or (1-6C)alkyl, and Q 4  is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl which optionally bears 1 or 2 substituents, which may be the same or different, selected from halogeno, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl and (1-6C)alkoxy,  
 and wherein any heterocyclyl group within a substituent on R 1  optionally bears 1 or 2 oxo or thioxo substituents;  
 n is 0, 1, 2 or 3;  
 each R 3  group is halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl,  N -(1 -6C)alkylcarbamoyl,  N,N -di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino,  N -(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino,  N -(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino,  N -(1-6C)alkyl-(3-6C)alkynoylamino,  N -(1-6C)alkylsulphamoyl,  N,N -di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino,  N -(1-6C)alkyl-(1-6C)alkanesulphonylamino or from a group of the formula:  
   —X 6 —R 11    
 wherein X 6  is a direct bond or is selected from O and N(R 12 ), wherein R 12  is hydrogen or (1-6C)alkyl, and R 11  is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl or di-[(1-6C)alkyl]amino-(1-6C)alkyl;  
 Z 2  is a C≡C or C(R 13 )═C(R 13 ) group, wherein each R 13  group, which may be the same or different, is hydrogen or (1-6C)alkyl; and  
 R 14  is selected from halogeno, cyano, isocyano, formyl, carboxy, carbamoyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxycarbonyl,  N -(1-6C)alkylcarbamoyl,  N,N -di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl,  N -(1-6C)alkylsulphamoyl,  N,N -di-[(1-6C)alkyl]sulphamoyl, halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl, (1-6C)alkoxycarbonylamino-(1-6C)alkyl or from a group of the formula:  
   —X 7 -Q 5    
 wherein X 7  is a direct bond or is selected from CO, CH(OR 15 ), CON(R 15 ) or SO 2 N(R 15 ), wherein R 15  is hydrogen or (1-6C)alkyl, and Q 5  is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,  
 and wherein any CH, CH 2  or CH 3  group within a R 14  substituent optionally bears on each said CH, CH 2  or CH 3  group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, amino, carboxy, carbamoyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl,  N -(1-6C)alkylcarbamoyl,  N,N -di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino,  N -(1-6C)alkyl-(2-6C)alkanoylamino,  N -(1-6C)alkylsulphamoyl,  N,N -di-[(1-6C)alkyl]-sulphamoyl, (1-6C)alkanesulphonylamino,  N -(1-6C)alkyl-(1-6C)alkanesulphonylamino or from a group of the formula:  
   —X 8 -Q 6    
 wherein X 8  is a direct bond or is selected from O, S, SO, SO 2 , N(R 16 ), CO, CH(OR 16 ), CON(R 16 ), N(R 16 )CO, SO 2 N(R 16 ), N(R 16 )SO 2 , C(R 16 ) 2 O, C(R 16 ) 2 S and N(R 16 )C(R 16 ) 2 , wherein R 16  is hydrogen or (1-6C)alkyl, and Q 6  is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,  
 and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on R 14  optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl,  N -(1-6C)alkylcarbamoyl,  N,N -di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino,  N -(1-6C)alkyl-(2-6C)alkanoylamino,  N -(1-6C)alkylsulphamoyl,  N,N -di-[(1-6C)alkyl]-sulphamoyl, (1-6C)alkanesulphonylamino,  N -(1-6C)alkyl-(1-6C)alkanesulphonylamino or from a group of the formula:  
   —X 9 —R 17    
 wherein X 9  is a direct bond or is selected from O and N(R 18 ), wherein R 18  is hydrogen or (1-6C)alkyl, and R 17  is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl ]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl, (1-6C)alkoxycarbonylamino-(1-6C)alkyl, or from a group of the formula:  
   —X 10 -Q 7    
 wherein X 10  is a direct bond or is selected from O, N(R 19 ) and CO, wherein R 19  is hydrogen or (1-6C)alkyl, and Q 7  is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl which optionally bears 1 or 2 substituents, which may be the same or different, selected from halogeno, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl and (1-6C)alkoxy,  
 and wherein any heterocyclyl group within a substituent on R 14  optionally bears 1 or 2 oxo or thioxo substituents;  
 or a pharmaceutically-acceptable salt thereof.  
 
   
   
       18 . The method of  claim 17  wherein said treatment and/or containment comprises producing an anti-invasive effect by administering to said animal said effective amount of a quinoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof.